Arrowhead Pharmaceuticals (ARWR) Asset Utilization Ratio (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Asset Utilization Ratio came in at 0.32 in Q1 2026, down 23.78% YoY from 0.42 in Q1 2025, and down 55.99% on a QoQ basis from 0.73 in Q4 2025.
Analysis
Arrowhead Pharmaceuticals (ARWR) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 16 years of Asset Utilization Ratio data on file, last reported at 0.32 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 23.78% year-over-year to 0.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.32 (down 23.78% YoY) and the FY2025 annual result came in at 0.66, up 17525.28% from the prior year.
- Asset Utilization Ratio fell to 0.32 in Q1 2026, from 0.73 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.73 in Q4 2025 to a low of 0.0 in Q4 2024.
- A 5-year average of 0.3 and a median of 0.32 in 2026 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio sank 99.11% — and 2025, when it soared 31335.92%.
- Tracing ARWR's Asset Utilization Ratio over 5 years: stood at 0.35 in 2022, then retreated by 25.72% to 0.26 in 2023, then slumped by 99.11% to 0.0 in 2024, then jumped by 31335.92% to 0.73 in 2025, then sank by 55.99% to 0.32 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.32 (Q1 2026), 0.73 (Q4 2025), and 0.6 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | 0.31 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.31 |
| Mar 31, 2026 | 0.32 |
| Dec 31, 2025 | 0.73 |
| Sep 30, 2025 | 0.60 |
| Jun 30, 2025 | 0.39 |
| Mar 31, 2025 | 0.42 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.02 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.26 |
| Sep 30, 2023 | 0.31 |
| Jun 30, 2023 | 0.30 |
| Mar 31, 2023 | 0.31 |
| Dec 31, 2022 | 0.35 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.34 |
| Mar 31, 2022 | 0.39 |
| Dec 31, 2021 | 0.21 |
| Sep 30, 2021 | 0.19 |